Partial Overlap of Anti-mycobacterial, and Anti-Saccharomyces Cerevisiae Mannan Antibodies in Crohn's Disease
Overview
Affiliations
Aim: To test whether humoral immune reaction against mycobacteria may play a role in anti-Saccharomyces cerevisiae antibodies (ASCA) generation in Crohn's disease (CD) and/or whether it correlates with clinical subtypes.
Methods: The dominant ASCA epitope was detected by Galanthus nivalis lectin (GNL)-binding assay. ASCA and IgG against mycobacterial lysates (M avium, M smegmatis, M chelonae, M bovis BCG, M avium ssp. paratuberculosis (MAP)] or purified lipoarabinomannans (LAM) were detected by ELISA. ASCA and anti-mycobacterial antibodies were affinity purified to assess cross-reactivities. Anti-mycobacterial IgG were induced by BCG-infection of mice.
Results: GNL bound to different extents to mycobacterial lysates, abundantly to purified mannose-capped (Man) LAM from M tuberculosis, but not to uncapped LAM from M smegmatis. Fifteen to 45% of CD patients but only 0%-6% of controls were seropositive against different mycobacterial antigens. Anti-mycobacterial IgG correlated with ASCA (r = 0.37-0.64; P = 0.003-P < 0.001). ASCA-positivity and deficiency for mannan-binding lectin synergistically associated with anti-mycobacterial IgG. In some patients, anti-mycobacterial antibodies represent cross-reactive ASCA. Vice-versa, the predominant fraction of ASCA did not cross-react with mycobacteria. Finally, fistulizing disease associated with antibodies against M avium, M smegmatis and MAP (P = 0.024, 0.004 and 0.045, respectively).
Conclusion: Similar to ASCA, seroreactivity against mycobacteria may define CD patients with complicated disease and a predisposition for immune responses against ubiquitous antigens. While in some patients anti-mycobacterial antibodies strongly cross-react with yeast mannan; these cross-reactive antibodies only represent a minor fraction of total ASCA. Thus, mycobacterial infection unlikely plays a role in ASCA induction.
Fungal microbiome in inflammatory bowel disease: a critical assessment.
Underhill D, Braun J J Clin Invest. 2022; 132(5).
PMID: 35229726 PMC: 8884899. DOI: 10.1172/JCI155786.
Verdier J, Deroche L, Allez M, Loy C, Biet F, Bodier C PLoS One. 2013; 8(5):e62780.
PMID: 23658774 PMC: 3642204. DOI: 10.1371/journal.pone.0062780.
Biet F, Gendt L, Anton E, Ballot E, Hugot J, Johanet C Dig Dis Sci. 2011; 56(6):1794-800.
PMID: 21221802 DOI: 10.1007/s10620-010-1523-8.